— Know what they know.
Not Investment Advice
Also trades as: 0HD2.L (LSE) · $vol 0M · DUL.DE (XETRA) · $vol 0M

ALNY Short Interest

Alnylam Pharmaceuticals, Inc.
1W: -2.4% 1M: -11.1% 3M: -21.1% YTD: -43.1% 1Y: -50.9% 3Y: +41.8% 5Y: +11.7%
$226.79
-0.87 (-0.38%)
After Hours: $226.09 (-0.70, -0.31%)
Weekly Expected Move ±5.6%
$199 $211 $224 $237 $249
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 38 · $30.5B mcap · 133M float · 1.26% daily turnover · Short 40% of daily vol
Credit Risk of going bust: lower than 72% of companies Debt: 4.0% of company value Bonds: $81.8M held by 45 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.82 (down 99.6%), Alnylam Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $1.27B against a stock market value of $30.46B.
Distance to default 7.98 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $505.5M (short-term plus half of long-term), stock volatility 51.3%; Altman Z'' 1.62. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Short Volume Summary

2026-10-26
28.7%
Short Ratio
of total volume
44.2%
20-Day Avg
58.0%
50-Day Avg
▲ Rising
5-Day Trend
0.2M
Short Volume
0.6M
Total Volume

Daily Short Volume Ratio

Short Volume vs Total Volume

Exchange Breakdown

2026-10-26
ExchangeShort VolumeTotal VolumeShort %
NASDAQ 165,016 583,549 28.3%
NYSE 10,339 26,727 38.7%
BATS 365 1,313 27.8%

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms